206 related articles for article (PubMed ID: 31189691)
1. Phosphoproteome Analysis Reveals Estrogen-ER Pathway as a Modulator of mTOR Activity Via DEPTOR.
Cuesta R; Gritsenko MA; Petyuk VA; Shukla AK; Tsai CF; Liu T; McDermott JE; Holz MK
Mol Cell Proteomics; 2019 Aug; 18(8):1607-1618. PubMed ID: 31189691
[TBL] [Abstract][Full Text] [Related]
2. microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.
Martin EC; Rhodes LV; Elliott S; Krebs AE; Nephew KP; Flemington EK; Collins-Burow BM; Burow ME
Mol Cancer; 2014 Oct; 13():229. PubMed ID: 25283550
[TBL] [Abstract][Full Text] [Related]
3. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
4. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
Hall BA; Kim TY; Skor MN; Conzen SD
Breast Cancer Res Treat; 2012 Sep; 135(2):469-79. PubMed ID: 22842983
[TBL] [Abstract][Full Text] [Related]
5. mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation.
Alayev A; Salamon RS; Berger SM; Schwartz NS; Cuesta R; Snyder RB; Holz MK
Oncogene; 2016 Jul; 35(27):3535-43. PubMed ID: 26522726
[TBL] [Abstract][Full Text] [Related]
6. The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo.
Shrivastav A; Bruce M; Jaksic D; Bader T; Seekallu S; Penner C; Nugent Z; Watson P; Murphy L
Breast Cancer Res; 2014 May; 16(3):R49. PubMed ID: 24887419
[TBL] [Abstract][Full Text] [Related]
7. TGFβ-induced deptor suppression recruits mTORC1 and not mTORC2 to enhance collagen I (α2) gene expression.
Das F; Bera A; Ghosh-Choudhury N; Abboud HE; Kasinath BS; Choudhury GG
PLoS One; 2014; 9(10):e109608. PubMed ID: 25333702
[TBL] [Abstract][Full Text] [Related]
8. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor α promotes protein synthesis by fine-tuning the expression of the eukaryotic translation initiation factor 3 subunit f (eIF3f).
Cuesta R; Berman AY; Alayev A; Holz MK
J Biol Chem; 2019 Feb; 294(7):2267-2278. PubMed ID: 30573685
[TBL] [Abstract][Full Text] [Related]
10. TIS21
Sundaramoorthy S; Devanand P; Ryu MS; Song KY; Noh DY; Lim IK
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1445-1462. PubMed ID: 29808317
[TBL] [Abstract][Full Text] [Related]
11. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
12. microRNA-181a downregulates deptor for TGFβ-induced glomerular mesangial cell hypertrophy and matrix protein expression.
Maity S; Bera A; Ghosh-Choudhury N; Das F; Kasinath BS; Choudhury GG
Exp Cell Res; 2018 Mar; 364(1):5-15. PubMed ID: 29397070
[TBL] [Abstract][Full Text] [Related]
13. DEPTOR is an in vivo tumor suppressor that inhibits prostate tumorigenesis via the inactivation of mTORC1/2 signals.
Chen X; Xiong X; Cui D; Yang F; Wei D; Li H; Shu J; Bi Y; Dai X; Gong L; Sun Y; Zhao Y
Oncogene; 2020 Feb; 39(7):1557-1571. PubMed ID: 31685947
[TBL] [Abstract][Full Text] [Related]
14. Dynamic modelling of the PI3K/MTOR signalling network uncovers biphasic dependence of mTORC1 activity on the mTORC2 subunit SIN1.
Ghomlaghi M; Yang G; Shin SY; James DE; Nguyen LK
PLoS Comput Biol; 2021 Sep; 17(9):e1008513. PubMed ID: 34529665
[TBL] [Abstract][Full Text] [Related]
15. DEPTOR Deficiency-Mediated mTORc1 Hyperactivation in Vascular Endothelial Cells Promotes Angiogenesis.
Ding Y; Shan L; Nai W; Lin X; Zhou L; Dong X; Wu H; Xiao M; Zhou X; Wang L; Li T; Fu Y; Lin Y; Jia C; Dai M; Bai X
Cell Physiol Biochem; 2018; 46(2):520-531. PubMed ID: 29614494
[TBL] [Abstract][Full Text] [Related]
16. DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma.
Yao H; Tang H; Zhang Y; Zhang QF; Liu XY; Liu YT; Gu WT; Zheng YZ; Shang HB; Wang Y; Huang JY; Wei YX; Zhang X; Zhang J; Wu ZB
Cancer Lett; 2019 Sep; 459():135-144. PubMed ID: 31176743
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction.
Kakiuchi Y; Yurube T; Kakutani K; Takada T; Ito M; Takeoka Y; Kanda Y; Miyazaki S; Kuroda R; Nishida K
Osteoarthritis Cartilage; 2019 Jun; 27(6):965-976. PubMed ID: 30716534
[TBL] [Abstract][Full Text] [Related]
18. Dynamic modelling of the mTOR signalling network reveals complex emergent behaviours conferred by DEPTOR.
Varusai TM; Nguyen LK
Sci Rep; 2018 Jan; 8(1):643. PubMed ID: 29330362
[TBL] [Abstract][Full Text] [Related]
19. Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration.
Razmara M; Monazzam A; Skogseid B
Cell Commun Signal; 2018 Oct; 16(1):64. PubMed ID: 30285764
[TBL] [Abstract][Full Text] [Related]
20. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
